Trending Now
Amicus Therapeutics (NASDAQ:FOLD) Announce Encouraging Preliminary AT-GTX-501 Gene Therapy Results In...
Amicus Therapeutics (NASDAQ:FOLD) has announced more positive preliminary data from the CLN6 Batten disease gene therapy program, AT-GTX-501.
Amicus presents AT-GTX-501 results
The released results were...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Liquidia Corporation (NASDAQ: LQDA) Announce Revenue of $3.9 million in Q2...
Liquidia Corporation (NASDAQ: LQDA) has announced its Q2 2022 financial results for the quarter ending June 30, 2022, and has also provided corporate updates.
Liquidia...
MAKE IT MODERN
LATEST REVIEWS
Skillz Inc (NYSE: SKLZ) Reports $85.9 Million Net Revenue in...
Skillz Inc (NYSE: SKLZ), a leading mobile games platform, recently announced its financial results for the three months that ended on June 30, 2021....
MAKE IT MODERN
PERFORMANCE TRAINING
Sorrento Therapeutics Inc. (NASDAQ: SRNE) Publishes Teasers Detailing Abivertinib’s Potential In COVID-19 And Cancer...
Sorrento Therapeutics Inc. (NASDAQ: SRNE) has published a Teaser entitled “Abivertiniv- a Franchise oral therapeutics for Cancer, COVID-190 and autoimmune Diseases.” The company plans...
Intellia Therapeutics Inc (NASDAQ: NTLA) Presented Preclinical Data on NTLA-6001
Intellia Therapeutics Inc (NASDAQ: NTLA) announced it presented preclinical data at the Precision Genome Engineering Conference, Keystone Symposia. The purpose of the presentation is...
Artelo Biosciences Inc (NASDAQ:ARTL) Posts Net Loss Of $951,395 In Q3 2020
Artelo Biosciences Inc (NASDAQ:ARTL) widened net loss by 175.80% to $951,395 in Q3 2020. Its operating expenses related to R&D, administrative and general expenses...
Cannabis Companies Could be Set to Flourish in 2022 (FLGC,HLF,HNST,NHTC)
The U.S. cannabis industry is growing at an unparalleled pace. Sales for 2021 are estimated to finish at $31 billion, an increase...
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP)’s Phase 3 DETERMINE Clinical Study Of Lenabasum Unable...
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) posted topline results of Phase 2 DETERMINE Clinical trial of Lenabasum in patients with heterogeneous and rare ADD...
MAKE IT MODERN
